News from the global pharmaceuticals industry about head lice treatments and corporate developments, including takeovers and mergers.
A study undertaken to determine the ovicidal efficacy of abametapir against eggs of both human head and body lice has revealed that abametaphir has an 100% ovicidal activity in vitro assessments and therefore able to inhibit hatching of both head and body louse eggs if used in specific concetrations.
TyraTech has reported an increase of 31% in sales during the first half of 2016.
The head lice brand Hedrin has announced the launch of a Stubborn Egg Loosening Lotion and suggested that this new addition to the Hedrin family would make it easy to remove dead eggs from the hair after treatment.
New commentary warns of the risks of excessive use of ivermectin for unauthorized groups.
Hatchtech is submitting its Xeglyze lice treatment to the FDA for approval and has signed a commercialisation agreement with Dr. Reddy’s.
DelveInsight have released an updated report covering the state of the pediculosis treatment pipeline.
Eden Research PLC has agreed a licensing deal with TerpeneTech Ltd granting exclusive use of its encapsulation technologies and other intellectual property for head lice treatments.
Tyratech have announced increased revenues for 2014, and are focussing more of their funding on Vamousse.
The patents concern methods for lice eradication via localised heat treatment, and are held by the University of Utah Research Federation, who have licensed them to Larada Sciences.
Larada Sciences developed AirAllé, a device for treating lice infection via heat treatment, which received FDA clearance in prior to its release with AirAllé branding in 2013.
The Second European Liceworld Seminar, which will take place in Copenhagen, Denmark, is on Thursday and Friday 10 – 11 September 2015. It will bring together international head lice experts and a broad variety of professionals for whom head lice play an important role in their working lives.